Product Name | Dapagliflozin (BMS-512148) |
---|---|
CAS | 461432-26-8 |
Formula | C21H25ClO6 |
MW | 408.87 |
Appearance | White to off-white powder |
Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
---|---|---|---|---|
500 mg | In-stock | $126.00 | Visible after login | |
1 g | 3-5days | $198.00 | Visible after login |
Product Name | Dapagliflozin (BMS-512148) |
---|---|
CAS | 461432-26-8 |
Formula | C21H25ClO6 |
MW | 408.87 |
Appearance | White to off-white powder |
Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Dapagliflozin (formerly known as BMS-512148; trade names Farxiga in the US and Forxiga in the EU) is a potent and selective hSGLT2 (sodium-glucose transport proteins) inhibitor with anti-diabetic activity. It inhibits hSGLT2 with an EC50 of 1.1 nM, and exhibits1200-fold selectivity over hSGLT1. Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Urine is the means by which blood glucose is expelled when this transporter mechanism is blocked.